ACW XanaMIA Alzheimers trial results
Released
Released
Announcement PDF
Actinogen Medical Limited ACN 086 778 476
Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000
+61 2 8964 7401 | actinogen.com.au
1
ASX ANNOUNCEMENT
Actinogen pivotal Alzheimer’s disease trial demonstrates trends toward clinical benefit
in older patients and favourable longer term safety profile
Sydney, 19 November 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) today announces
topline results from its pivotal, placebo-controlled XanaMIA trial of oral emestedastat (Xanamem®) over 36
weeks of treatment in 247 patients with mild to moderate Alzheimer’s disease (AD) and elevated levels of the
pTau181 blood biomarker.
Summary:
• In the overall population, Xanamem was numerically, but not statistically, superior to placebo for the
primary endpoint of delayed disease progression, measured by the Clinical Dementia Rating Scale –
Sum of Boxes (CDR-SB)
• Clinically significant and sustained benefit of 30% disease slowing was observed in older participants,
supporting a new patent filing covering Xanamem treatment in older, more advanced AD patients, who
are underserved by existing therapies and newer ones in development
• Xanamem was safe and well tolerated over the treatment period of 36 weeks
• In the Open Label Extension (OLE) phase of the trial, disease stabilization over 24 weeks (no mean
progression) was observed in the first 29 participants with 24 weeks of active Xanamem therapy and
therefore the OLE phase will continue in order to gather additional data
• The next OLE data milestone to be reported when approximately 100 participants have reached at
least 24 weeks of treatment (Q1 CY2027)
• The Company is well-funded to CY2028, with $18.9m1 cash on hand and no debt.
Detailed findings from the topline XanaMIA trial results are:
1. Xanamem was numerically, but not statistically, superior to placebo for the primary endpoint of delayed
disease progression, measured by the CDR-SB at Weeks 12, 24 and 36, with a mean Xanamem
benefit compared with placebo of 0.10 CDR-SB points at Week 36 (p = 0.65)
2. A statistically and clinically significant benefit on the CDR-SB zero progression rate (40% vs. 22%,
p=0.02) for Xanamem was observed in the prespecified analysis of participants above the median age
of 75 years, together with a clinically significant benefit of 30% disease slowing (mean CDR-SB
superiority of 0.39 points at Week 36, p=0.22) – for context, this rate of disease slowing is similar to
that claimed by Eli Lilly and Eisai for their approved anti-amyloid drugs
3. Small trends towards superiority of Xanamem vs. placebo on the key secondary endpoints of cognition
and “Activities of Daily Living” were observed
4. The previously established, favourable safety profile for Xanamem 10 mg administered daily for up to
12 weeks was replicated over the longer treatment period of 36 weeks and no serious adverse events
were attributed to Xanamem
®
Xanamem is a registered trademark of Actinogen Medical Limited
1
Unless stated otherwise, all financial data is in Australian dollars
Actinogen Medical Limited ACN 086 778 476
Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000
+61 2 8964 7401 | actinogen.com.au
2
5. Unblinding of data used by the Independent Data Monitoring Committee (DMC) in January 2026, for
its interim analysis of trial-futility, showed a statistically significant Xanamem treatment benefit of 0.58
points (p=0.03, n=88) on the prespecified, interim analysis Week 24 CDR-SB endpoint, which was not
fully sustained in the final analysis of 247 participants.
Available data from the XanaMIA OLE phase of the trial has also been reviewed and shows an encouraging
lack of progression in the CDR-SB at 24 weeks in the first 29 participants to reach that timepoint. Continuation
of the OLE phase will provide important long-term data on Xanamem treatment and aims to demonstrate
durable treatment benefits. The next OLE data milestone will be reported in Q1CY2027 when approximately
100 participants have reached at least 24 weeks.
The Company intends to explore the XanaMIA results with potential co-development partners interested in
novel AD therapies, with a focus on the encouraging data observed for older participants, who represent more
than 70% of patients with Alzheimer’s disease. Given its established safety profile in more than 500 participants
and lack of drug-drug interaction potential, Xanamem is particularly well suited as a treatment for the older,
more complex AD population, most of whom are on multiple medications including older AD treatments like
donepezil.
Immediate steps have been taken to conserve cash by focusing expenditure on the OLE trial, suspending
future phase 3 expenditure, expanding the intellectual property portfolio to include the new XanaMIA trial
finding on older age, business development outreach, strategic portfolio planning, and finalizing XanaMIA
analyses.
As of the date of this announcement, the Company had a cash balance of $18.9 million, and a significant
accrued R&D tax incentive given the substantial amount of eligible R&D spend undertaken in the first half of
FY2027. As the XanaMIA trial is closed out and with other cost saving initiatives being undertaken, the
Company’s cash commitments will drop substantially from early CY2027. The Company has no debt. This
strong balance sheet provides a cash runway into CY2028 and enables the Company to complete evaluation
of the XanaMIA data to determine the optimal strategy for the future development of Xanamem.
Actinogen’s CEO, Dr Steven Gourlay, commented:
“Following our topline analysis of the XanaMIA trial we remain confident in the risk-benefit profile of Xanamem
in mild to moderate Alzheimer’s disease, with notable findings of clinically significant disease slowing in older
participants, who represent a poorly served and large segment of the market. Our strong balance sheet
provides optionality to fully explore the trial data with potential partners over the coming months and determine
the optimal development path for Xanamem. We sincerely thank everyone for their ongoing support of
Xanamem development including patients and their families living with Alzheimer’s disease, as well our
shareholders.”
The Company will be holding a webinar at 11.00am (AEDT) this morning to discuss the trial results. Register
for the webinar at any time through to the 11.00am start at: https://tinyurl.com/mr3js44b
A recording of the webinar will be available on the Company’s InvestorHub site and YouTube channel as soon
as possible following the event.
A copy of the webinar presentation is attached to this announcement.
View this announcement on our InvestorHub: https://investors.actinogen.com.au/link/Pmodbe
ENDS
Actinogen Medical Limited ACN 086 778 476
Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000
+61 2 8964 7401 | actinogen.com.au
3
Investors Media
Dr Steven Gourlay Michael Roberts George Hazim
CEO & Managing Director Communications Media & Public Affairs Australia
P: +61 2 8964 7401 M: +61 423 866 231 M: +61 417 516 262
E. steven.gourlay@actinogen.com.au E. michael.roberts@actinogen.com.au E: georgehazim@mediaaffairs.com.au
Announcement authorised by the Board of Actinogen Medical Limited
About Actinogen Medical
Actinogen Medical (ACW) is an ASX-listed, biotechnology company in the late clinical stages of development for
Xanamem® (emestedastat), its novel oral therapy for Alzheimer’s disease. Xanamem also has other applications in
diseases driven by elevated tissue cortisol including depression. The Company is based in Sydney, Australia with
operations and clinical trials in Australia and the US. Xanamem has been studied in eight clinical trials with more than 500
people treated to date and has a promising safety and efficacy profile with treatment up to 36 weeks.
About the phase 2b/3 XanaMIA pivotal trial and Open Label Extension (OLE) phase
The XanaMIA trial was a randomized (1:1), double-blind, placebo-controlled phase 2b/3 trial evaluating Xanamem 10 mg
versus placebo over 36 weeks in 247 participants across Australia and the United States. On 19 November 2026 Actinogen
reported the initial results from the trial, showing trends towards overall slowing of disease progression and clinically
significant slowing in older participants. Further analyses are on-going. The OLE phase of the trial is on-going following
closure of enrolment of 168 participants in November 2026.
About Xanamem (emestedastat)
Xanamem’s novel mechanism of action is to control the level of cortisol in brain, liver and adipose tissue (fat) through the
inhibition of the tissue cortisol synthesis enzyme, 11β-HSD1, without blocking normal production of cortisol by the adrenal
glands. Xanamem is a first-in-class, once-a-day pill designed to deliver high levels of tissue cortisol control in regions where
11β-HSD1 is highly expressed such as the hippocampus and grey matter in the brain, as well as in liver and adipose tissue.
Chronically elevated cortisol is associated with progression in Alzheimer’s Disease and excess cortisol is known to be toxic
to brain cells. Elevated cortisol is also associated with more severe forms of depression. Xanamem has demonstrated
excellent target enzyme engagement and in human trials has shown potential benefit in older people with Alzheimer’s
disease and anti-depressive benefits in patients with moderately severe depression. To view Xanamem’s two-minute
Mechanism of Action animation, click here.
Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global
regulatory authority. Xanamem® is a trademark of Actinogen Medical.
Disclaimer
This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are
based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken
place and may not take place. Such forward looking statements should be considered “at-risk statements” - not to be relied
upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business,
economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes
and uncertainties) that may lead to actual results being materially different from any forward looking statement or the
performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on
these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any
obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to
reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future
performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of
achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any
forward-looking statements will be realized.
ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS
WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.
XanaMIA Alzheimer’s disease trial demonstrates
clinically significant trend toward benefit in participants
over 75 years but not in overall trial population
Xanamem demonstrates good long-term safety and tolerability with a
promising rate of disease slowing in older Alzheimer’s patients
Topline Results Webinar 19 November 2026
Disclaimer
This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and
does not contain all information necessary to make an investment decision.
This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual’s
investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations.
Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their
jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.
Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the
fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any
other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information
contained in this presentation or otherwise arising in connection with it.
The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation,
which may affect any matter referred to in this presentation.
This presentation is not for general distribution or third party reliance or use.
This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management
in respect of which there is NO guarantee of future performance. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or
performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its
clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and
global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is
no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of
our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Actinogen will operate
in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward
looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place
undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of or non-occurrence of any events.
Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in
Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends.
To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (Parties) exclude all direct and indirect liability arising out of or in connection with any use or
reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express
or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or
any accompanying, previous or subsequent material or presentation.
2
XanaMIA results webinar 19 Nov 2026
XanaMIA results webinar 19 Nov 2026
3
XanaMIA results webinar 19 Nov 2026
XanaMIA trial design and methods
4
Primary Endpoint Key Secondary Endpoints
CDR-SB change from baseline to 36 weeks Change from Baseline to Week 36 in:
• Global Cognitive Test Battery (CTB)
• Amsterdam Instrumental Activities of Daily Living
Questionnaire – short version (A-IADL-Q-SV)
XanaMIA results webinar 19 Nov 2026
A double-blind, randomized, 36-week, 2-arm clinical trial to assess safety, tolerability,
and efficacy of Xanamem 10 mg daily in patients with mild to moderate AD (MMSE 18-26)
Weeks
40
-4 0 36
10mg Xanamem
Placebo
Screening
Double-blind, randomised treatment
period (N=247)
Follow-up &
open label
-10
Pre-screening
Key baseline characteristics for overall population
Generally well-balanced between groups
XanaMIA results webinar 19 Nov 2026 5
Xanamem Placebo
Age (mean, SD) 75.4 (7.5) 73.4 (8.6)
Sex, female (N, %) 63 (51.2) 57 (46.3)
Concomitant AD medications, yes (N, %) 74 (60.2) 75 (61)
ApoE4 carriers (N, %) 93 (75.6) 77 (62.6)
MMSE Total Score (mean, SD) 21.8 (3.4) 21.8 (3.1)
CDR-SB Score (mean, SD) 4.27 (1.84) 4.29 (2.09)
pTau-181 level (pg/ml) (mean, SD) 3.02 (2.13) 2.75 (1.22)
pTau-217 level (pg/ml) (mean, SD) 0.98 (1.32) 0.81 (0.48)
Primary endpoint: small overall CDR-SB benefit
Effect size 0.10 points at end of treatment, not statistically significant (p = 0.65 Week 36)
6
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Baseline Week 12 Week 24 Week 36
Xanamem (n = 123) Placebo (n=123)
CDR-SB LS mean change
from baseline (± SE)
Worsening
0.10-point benefit
XanaMIA results webinar 19 Nov 2026
7
CDR-SB
LS
mean
change
from
baseline
(±
SE)
Worsening
Age > median at baseline
Age ≤ median at baseline
Major Xanamem trend in prespecified age > 75 years
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Baseline Week 12 Week 24 Week 36
Xanamem (n=55) Placebo (n=66)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Baseline Week 12 Week 24 Week 36
Xanamem (n=65) Placebo (n=57)
CDR-SB effect size 0.39 points, p = 0.22 at Week 36
* 30% slowing similar to approved antibody therapies; older people have higher 11β-HSD1
XanaMIA results webinar 19 Nov 2026
30% slowing of
progression*
Clear benefits in response rates in older participants
40% Xanamem stable (no progression) vs. 22% Placebo for age > 75 years*
8
Percentage responders
37
40
24
22
0
5
10
15
20
25
30
35
40
45
50
> 70 stable > 75 stable
Xanamem Placebo
*p = 0.02
* Statistically significant: rate of stable or improved score of CDR-SB at end of treatment; donanemab data Sims et al. 2023 XanaMIA results webinar 19 Nov 2026
For context, stable disease claim in donanemab trials is similar at 47% vs. 29% at one year
• 5.5 million Americans age 75+ live with Alzheimer’s, accounting for 74% of U.S. cases
among adults 65 and older. [1]
• ~80% of Alzheimer’s cases among adults ages 75–84 were mild or moderate. [2]
• Recently approved Alzheimer’s drugs are for earlier stage disease called “Mild Cognitive
Impairment” as well as “Mild Alzheimer’s disease” – e.g. early intravenous lecanemab
uptake was about 80% lower at age 75+ than at ages 66–74. [3, 4]
• An estimated 32 million people had Alzheimer’s disease worldwide in 2020. By 2050, the
global population age 80+ is projected to triple to 426 million. [5, 6]
Major unmet need in Alzheimer’s care for adults older than 75
Alzheimer’s patients older than 75 represent more than two thirds of the market
[1] Alzheimer’s Association, 2026 Facts and Figures, Fig. 4. [2] Yuan et al., J Alzheimers Dis, 2021. [3] U.S. prescribing information for Leqembi and Kisunla, §1. [4]
Zhou et al., JAMA Network Open, 2025. [5] Gustavsson et al., Alzheimer’s & Dementia, 2023, Table 3. [6] WHO, Ageing and health, 2025.
XanaMIA results
webinar 19 Nov 2026
9
Slight benefit of Xanamem on cognition
Cognitive performance measured by computerized testing, p = 0.59
10
Global CTB LS mean change
from baseline (± SE)
Worsening
-0.15
-0.1
-0.05
0
0.05
0.1
Baseline Week 4 Week 12 Week 24 Week 36
Xanamem Placebo
XanaMIA results webinar 19 Nov 2026
Slight benefit on daily functioning overall
11
-3
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
Baseline Week 12 Week 24 Week 36
Xanamem (n=123) Placebo (n=123)
A-IADL-Q-SV LS mean change
from baseline (± SE)
Worsening
A-IADL-Q-SV “Amsterdam” activities of daily living questionnaire
XanaMIA results webinar 19 Nov 2026
Other preliminary findings
• Available data from the XanaMIA OLE phase indicates disease stabilization in the mean
CDR-SB in the first 29 participants who have reached 24 weeks on active Xanamem
• Trends towards reduction in neuroinflammation markers GFAP, neurofilament light
• No trends towards reduction in Alzheimer’s disease biomarkers such as pTau
• Excellent safety profile consistent with prior trials
• No serious adverse events attributed to Xanamem
12
XanaMIA results webinar 19 Nov 2026
The XanaMIA interim analysis was strongly positive
Effect sizes 0.58 at Week 24, p = 0.03; 0.38 at Week 36, p = 0.39
13
CDR-SB LS mean change
from baseline (± SE)
Worsening
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Baseline Week 12 Week 24 Week 36
Xanamem Placebo
Week 12 Week 24 Week 36
n (Xanamem) 70 43 29
n (Placebo) 72 45 23
XanaMIA results webinar 19 Nov 2026
Conclusion
• The Company sincerely thanks everyone who has supported Xanamem development up to this point
including patients and their families living with Alzheimer’s disease, as well our shareholders
• The risk-benefit profile of Xanamem is highly suited to treatment in mild to moderate Alzheimer’s
disease, with notable findings of activity in older participants, who represent a poorly served and large
segment of the market
• In patients over 75 a statistically significant disease stabilization rate was observed together with
disease slowing of 30% (for comparison, Eli Lilly claim 22% for donanemab, Eisai 27% for lecanemab)
• The Open Label Extension (OLE) phase disease shows stabilization over 24 weeks (no mean
progression) in the first 29 participants on Xanamem - OLE phase to continue
• Next OLE milestone when approximately 100 participants reach ≥24 weeks of treatment (Q1 CY2027)
• Balance sheet (cash balance $18.9 million and no debt) provides optionality to fully explore the trial data
with potential partners over the coming months and determine the optimal development path for
Xanamem
XanaMIA results webinar 19 Nov 2026 14
XanaMIA results webinar 19 Nov 2026 15
XanaMIA results webinar 19 Nov 2026
Contacts
Will Souter
CFO & Investor Relations
M: +61 402 035 716
E. will.souter@actinogen.com.au
Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E. steven.gourlay@actinogen.com.au
Join the Actinogen Investor Hub:
https://investors.actinogen.com.au/
16
XanaMIA results webinar 19 Nov 2026
Share your feedback
Discover